Nai-Kong V. Cheung, MD, PhD
Selected Publications
Lu YG, Cheung NK, Fu BM. A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases. Journal of Nuclear Medicine 2009; 50 :1324-1331
Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors. Cancer Research 2009; 69 :6275
Gershon TR, Shirazi A, Qin LQ, Gerald WL, Kenney AN, Cheung NKC. . Enteric Neural Crest Differentiation in Ganglioneuromas Implicates Hedgehog Signaling in Peripheral Neuroblastic Tumor Pathogenesis.. PloS One 2009; (in press) : Hu J, Huang XD, Ling CC, Bundle, Cheung NKV. . Reducing Epitope Spread during Affinity Maturation of an Anti-ganglioside GD2 Antibody. Journal of Immunology 2009; (in press) : Tassev DV and Cheung NKV. Monoclonal antibody therapies for solid tumors. Expert Opinion On Biological Therapy (Informa Healthcare) 2009; 9 :341-53
Hu J, Cheung NK. Methionine depletion with recombinant methioninase: In vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. International J. of Cancer 124:1700-1706, 2009.
Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman J, Budak-Aldogan T, Karpikov A, Guo HF, Flavell RA, Cheung NK, Weissman SM, Bahceci E. Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes. Human Gene Therapy, 2008. (in press)
Kushner BH, Cheung NK. Neuroblastoma: Linking a Common Allele to a Rare Disease. New England Journal of Medicine 358:2585-2593, 2008.
Modak S, Kushner BH, Laquaglia MP, Kramer K, Cheung NK. Management and outcome of INSS stage 3 neuroblastoma. European J. of Cancer, 45:90-98, 2008.
Kushner BH, Kramer K, Modak S, and Cheung NKV. Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma. J. Clinical Oncology, 27:1041-1046, 2008.
Cheung NK. Chapter 34. Therapeutic antibodies and immunologic conjugates. In Clinical Oncology 4th ed. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (ed). Elsevier, Churchill, Livingstone. 2008. Luther N, Cheung NK, Dunkel IJ, Fraser JF, Edgar MA, Gutin PH, Souweidane MM. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery, 63:1166-1174, 2008.
Cheung IY, Feng Y, Gerald W, Cheung NK. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clinical Cancer Research, 14:7020-7027, 2008.
Cheung IY, Feng Y, Danis K, Shukla N, Meyers P, Ladanyi M, Cheung NK. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling Clinical Cancer Research, 13:6978-6983, 2007.
Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Phase I study of targeted radioimmunotherapy for Leptomeningeal Cancers using Intra-Ommaya 131I-3F8. Journal of Clinical Oncology 25:5465, 2007.
Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 25(1):67-77, 2007.
Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK. Cyclin D1: A novel molecular marker of minimal residual disease in metastatic neuroblastoma. Journal of Molecular Diagnostics. 9:237-241. 2007.
Oppenheimer O, Cheung NK, Gerald WL. Transcriptional programs associated with retinoic acid induced differentiation in neuroblastoma. Mol Cancer Ther 6(4):1300-1309, 2007.
Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A Polymorphism Is Correlated With Clinical Outcome Following Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor. J Clinical Oncology 24:2885-2890, 2006.
Cheung IY, Vickers A, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. International Journal of Cancer 119:152-156, 2006.
Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1->3)(1->4)-D-Beta-glucan. Leukemia Research, 29: 679-683, 2005.
Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors. J Nucl Med 2005; 46(1Suppl) :157S-63S Kushner BH, Cheung NK. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 47:863-864, 2006.
Kushner BH, Cheung NK.. Neuroblastoma--from genetic profiles to clinical challenge. New England Journal of Medicine 353: 2215-2217, 2005.
Return to Nai-Kong V. Cheung, MD, PhD Main Page.
|
|
